eras-601,cetuximab,pembrolizumab
merck,eli lilly,erasca
['flagshp-1', 'cetuximab', 'eras-601']
erasca presents promising initial phase 1b dose escalation data from flagshp-1 for eras-601 plus cetuximab in patien 